Exploration of Feasability of Blood and Saliva Proteomic Analysis Through Harvesting by Silica Matrix (NanoDx-CoV-19)
NCT ID: NCT04597216
Last Updated: 2020-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2020-10-15
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
25 patients with a PCR-based diagnosis of Covid-19 will be be included to give 500 microliters of saliva and a 3 ml sample of blood for proteomic analysis; a drop of blood will also be put in a device connected to a silica matrix to perform spectrometric analyses. 25 patients with a non-Covid-19 respiratory infection will be included for the same samples. The proteomic analyses will be performed from classicaly draught blood, blood drop on silica, and saliva, to search for discriminating profiles between Covid-19 and non-Covid-19.
Phase 2:
150 patients with a suspected Covid-19 will be included at the same time than the Covid-19PCR is performed ; they will have a sample of saliva and of a drop of blood for proteomic analysis, whose results will be matched with PCR results.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept
NCT04780334
Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19
NCT04405492
Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System
NCT04311398
Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test
NCT04597047
SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study
NCT05492227
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase 2: confirmation analyses 150 patients with a suspected Covid-19 will be included at the same time than the Covid-19PCR is performed ; they will have a sample of saliva and of a drop of blood for proteomic analysis, whose results will be matched with PCR results.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
unique arm
there is only 1 arm in this study (all the participants will undergo the same diagnosis procedure)
sample of blood and saliva
sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sample of blood and saliva
sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinical signs evocative of Covid-19
* negative Covid-19 PCR
* acute respiratory infection
* suspicion of Covid-19
* sample for Covid-19 PCR planned or performed the same day
Exclusion Criteria
* none
Phase 2
* past known Covid-19
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
olivier EPAULARD
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC20.289
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.